News Updates
More Articles
- The Pitfalls and Promise of Cell and Gene Therapy Development: A Time for Concerted Action
- “Not Just Checking a Box”: A Call to Rethink Patient Involvement in the EU
- From Cells to Animals and Back Again: The Shifting Landscape of Cancer Efficacy and Safety Models
- Addressing Inequity: Embedding Inclusion and Diversity in UK Clinical Trials
- The Next AI Revolution: Computer System Validation
Have Your Say: EMA`s Draft Reflection Paper on Patient Experience Data (PED) Now Open for Consultation
The European Medicines Agency (EMA) recently acknowledged the usefulness of Patient Experience Data (PED) in a draft reflection paper open for public comment until January 31, 2026.